Nabriva is a commercial-stage biopharmaceutical company engaged in the research & development of novel antibiotics to treat serious infections, with a current focus on the pleuromutilin class of antibiotics. Learn more at Nabriva.com
Location: United States, California, San Diego
Total raised: $65M
Investors 1
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.09.2016 | - | $10M | - |
| 30.03.2016 | Series A | $45M | - |
| 23.12.2015 | - | $10M | - |
Mentions in press and media 12
| Date | Title | Description |
| 27.03.2017 | A lot to GAIN: Zavante awaits pivotal data on retro-antibiotic | It was that dire lack of options that led to a bipartisan initiative dubbed the Generating Antibiotics Incentives Now Act (GAIN Act), signed into effect in 2012. That year, the CDC estimates some 23,000 Americans died from antibiotic-resist... |
| 01.09.2016 | Zavante Therapeutics Receives $10M Credit Facility from Square 1 Bank | Zavante Therapeutics, a San Diego, CA-based clinical-stage biotechnology company, received a $10m credit facility. Square 1 Bank, a division of Pacific Western Bank, provided the financing. The company intends to use the funds to file a New... |
| 01.09.2016 | Zavante Therapeutics Secures $10 Million Loan | Zavante Therapeutics, a San Diego startup launched by biotech veterans last fall, has secured a $10 million loan from Square 1 Bank, a division of Pacific Western Bank. The new funds will be used for growth and commercialization, according ... |
| 30.03.2016 | Daily funding roundup - March 30, 2016 | Zavante closed $45M Series A funding; MapD secured $10M; Invoca closed $30M Series D funding Invoca, a marketing platform for call analytics and automation, closed a $30 million Series D round of funding led by Morgan Stanley Alternative In... |
| 30.03.2016 | Zavante Therapeutics Gets $45M | San Diego-based Zavante Therapeutics, a biopharmaceuticals firm developing injectable antibiotics, has raised $45M in a Series A financing round. Zavante said the investment was led by Frazier Healthcare Partners and Longitude Capital, and ... |
| 30.03.2016 | Zavante raises $45M to bring antibiotic fosfomycin to U.S. | However, there’s nothing like fosfomycin on the U.S. market, CEO Ted Schroeder said in a phone interview. The drug’s a first-in-class epoxide injectable antibiotic that’s shown, for decades, activity against both Gram-positive and Gram-nega... |
| 30.03.2016 | Zavante Therapeutics Closes $45M Series A Financing | Zavante Therapeutics, Inc., a San Diego, CA-based late clinical-stage biopharmaceutical company, closed a $45m Series A financing. This included $35m from new investors and $10m from the conversion of outstanding convertible notes. Backers ... |
| 30.03.2016 | Zavante Therapeutics Closes $45M Series A | SAN DIEGO, CA, Privately held, late clinical-stage biopharmaceutical company, today announced that it has closed a $45 million Series A financing. >> Click here for more funding data on Zavante Therapeutics >> To export Zava... |
| 23.12.2015 | Zavante gets $10M for CRE-treating antibiotic to enter clinic | Zavante says that ZTI-01 is a novel antibiotic that has both Gram-positive and Gram-negative activity – and is showing efficacy in treating dangerous Carbapenem Resistant Enterobactericeae, or CRE. The company writes of its regulatory miles... |
| - | A lot to GAIN: Zavante awaits pivotal data on retro-antibiotic | When the current drugs stop working and there’s a shortage of anything new, what options does the medical community have to combat antibiotic resistance? Circa 2010, the answer was ‘not a lot.’ It was that dire lack of options that led to a... |
Show more